Evidence map›Paper›PMID 33492345›Full record

ArticleThe Journal of general physiology2021

Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin.

Larry S Tobacman, Anthony Cammarato

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of general physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. HomozygousGenes · 2023
    Review
  13. Article
  14. Article
  15. The effect of MgThe FEBS journal · 2022
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Larry S TobacmanDepartments of Medicine and of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL.
Anthony CammaratoDepartments of Medicine and of Physiology, Johns Hopkins University, Baltimore, MD.
Johns Hopkins University · USUniversity of Illinois Chicago · US

Funding

THIN FILAMENTS WITH CARDIOMYOPATHIC MUTANT PROTEINSR01HL063774 · NHLBI · UNIVERSITY OF IOWA · PI TOBACMAN, LARRY S · 2000 to 2014
$4.5M
PATHOGENESIS AND IN VIVO SUPPRESSION OF THIN FILAMENT-BASED CARDIOMYOPATHIESR01HL124091 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Anthony Cammarato · 2015 to 2026
$4.3M
Pathogenesis and in vivo suppression of thin filament based cardiomyopathiesR56HL124091 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CAMMARATO, ANTHONY · 2014 to 2014
$383k
NHLBI NIH HHS R01 HL063774NHLBI NIH HHS R01 HL124091NHLBI NIH HHS R56 HL124091
6 · The paper itself

Abstract

Reversible Ca2+ binding to troponin is the primary on-off switch of the contractile apparatus of striated muscles, including the heart. Dominant missense mutations in human cardiac troponin genes are among the causes of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. Structural understanding of troponin action has recently advanced considerably via electron microscopy and molecular dynamics studies of the thin filament. As a result, it is now possible to examine cardiomyopathy-inducing troponin mutations in thin-filament structural context, and from that to seek new insight into pathogenesis and into the troponin regulatory mechanism. We compiled from consortium reports a representative set of troponin mutation sites whose pathogenicity was determined using standardized clinical genetics criteria. Another set of sites, apparently tolerant of amino acid substitutions, was compiled from the gnomAD v2 database. Pathogenic substitutions occurred predominantly in the areas of troponin that contact actin or tropomyosin, including, but not limited to, two regions of newly proposed structure and long-known implication in cardiomyopathy: the C-terminal third of troponin I and a part of the troponin T N terminus. The pathogenic mutations were located in troponin regions that prevent contraction under low Ca2+ concentration conditions. These regions contribute to Ca2+-regulated steric hindrance of myosin by the combined effects of troponin and tropomyosin. Loss-of-function mutations within these parts of troponin result in loss of inhibition, consistent with the hypercontractile phenotype characteristic of HCM. Notably, pathogenic mutations are absent in our dataset from the Ca2+-binding, activation-producing troponin C (TnC) N-lobe, which controls contraction by a multi-faceted mechanism. Apparently benign mutations are also diminished in the TnC N-lobe, suggesting mutations are poorly tolerated in that critical domain.

Indexed as

CardiomyopathiesTropomyosinActin CytoskeletonActinsCalciumHumansMutationTroponin ITroponin TActinsCalciumTropomyosinTroponin ITroponin T

Identifiers

PMID33492345
PMCPMC7836260
OpenAlexW3122027059

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.